Skip to main content
. 2006 Oct;80(19):9779–9788. doi: 10.1128/JVI.00794-06

TABLE 2.

HIV-1 epitopes recognized by study participant CD8+ T cells before and after HIV-1 infection

Participant identifier Vaccine treatment Class I HLA type Days postinfection Viral load RNA (copies/ml) HIV-1 epitopei IFN-γ SFC/ 106 PBMC
Before After
014A-003 Placebo A*0101, A*2902; B*1501, B*5701 58 1,525 Gag TSTLQEQIGW <20 125
014A-006 Placebo A*0101; B*0801, B*1401 59 1,749,235 Env IVELLGRRGWEVLKY <20 1,790
Env RQGLERALL <20 2,835
Env ERYLKDQQL <20 2,350
Nef FLKEKGGL <20 695
Nef AAVDLSHFL <20 2,545
402FIEa Placebo A3, A32; B38, B64 60 2,069 Gag RLRPGGKKK <20 137
Gag VDRFYKTLRAEQASQ <20 690
Env MHEDIISLW <20 280
Vpr GLGQHIYETYGDTWAe <20 260
014A-001 vCP205/gp120 A*0202, A*8001; B*1801, B*5301 64 NAb Gag QAISPRTLNAW <20 103
Env RIRQGLERA <20 373
Nef YPLTFGWCY <20 113
014A-004 vCP205 A*0201, A*1101; B*4002, B*5101 46 <50 Pol TAFTIPSI <20 210
Gag CTERQANFL 129 70
Gag SLYNTVATLh 47 149
Nef AVDLSHFLK 74 740
014A-005 vCP205/gp120 A*2501, A*3002; B*0702, B*1801 71 65,775 Gag QAISPRTLNAW <20 358
Gag ETINEEAAEW <20 363
Env TENFNMWKNNMVEQM <20 585
Env IPRRIRQGL <20 943
Nef FPVTPQVPLR <20 558
Tat CCFHCQVC <20 408
Pol QKQGQGQWTYQIYQE <20 165
Pol KIQNFRVYY <20 435
Vpr EAVRHFPRIWLHGLG <20 490
014A-008 vCP205 A*0201, A*0301; B*4501, B*5301 106 130,483 Gag RLRPGGKKK <20 220
014A-009 vCP205 A1, A2; B8, B38 87 12,413 Gag EIYKRWII <20 290
Env MHEDIISLW <20 300
Env RRGWEVLKY <20 115
Env RQGLERALL <20 240
Nef IHSQRRQDILDLWIY <20 125
014A-011 vCP205 A*0201; B*31012, B*1501 122 <400c None
40287N vCP125/gp120 A1, A33; B8, B44 318 17,392 Gag GGKKKYKL <20 570
Gag EIYKRWII <20 150
Vpr EAVRHFPRIWLHGLG <20 160
Vpu EYRKILRQRKIDRLI <20 120
402I03f vCP65/gp120 A3, A33; B15 (63), B27 242 2,109 Gag IRLRPGGKK <20 3,960
Gag KRWIILGLNK <20 5,310
Gag GLNKIVRMY <20 570
Gag MMQRGNFRNQRKIVKe <20 2,510
Env SFNCGGEFF <20 750
Env LQRAGRAILHIPTRI <20 190
402I15 vCP205 A1, A10 (26); B8, B17 (57) 92 41,742d Gag QMVHQAISPRTLNAWe <20 300
Rev DEELIRTVRLIKLLYe <20 330
Nef FLKEKGGL <20 480
403-006 vCP205/gp160 A2, A2; B62, B35 141 3,069 Gag PPIPVGDIY <20 95
Vif DAKLVITTY <20 95
2x0226 vCP205/gp120 NAb 30 NAb Vif DAKLVITTY <20 2,943
Env PIPIHYCAPAGFAIL <20 153
203-033 vCP1452 A*2501, A*6601; B*0702, B*1801 39 165,509d Noneg
203-157 vCP1452/gp120 A*3001, A*3002; B*4201/02, B*4403/26/30 91 32,511d Pol YPGIKVRQL NDj 490
Pol KIQNFRVYY 365
Pol DDTVLEEMSLPGRWK 215
a

Some responses mapped in this individual at 143 dpi (viral load of <400 and participant on ART).

b

NA, data not available.

c

On ART at time of mapping.

d

No viral load was obtained on the visit date of sample collection. Thus, the closest viral load reported for 402I15 was 3.3 months post-sample date; for 203-033, it was 0.4 months post-sample date; for 203-157, it was 0.7 months post-sample date.

e

By matrix only. The individual peptide was not tested due to insufficient cells.

f

Responses to Vif and Vpr peptide pools were not tested in this individual. Pol pools 9 and 10 were also positive, but an exact peptide(s) was not identified due to insufficient cells.

g

Only a weak PHA response (587 SFC/106 PBMC) was detected at this time point.

h

See later figures and Discussion.

i

The vaccine contained the epitopes shown in bold.

j

ND, not determined.